Brca1 Mutasyonlu Over Kanserinde Hotaır–Mir-34a–CCND1 Ekseninin Fonksiyonel ve Klinik Önemi

Yıl 2025, Cilt: 16 Sayı: 4, 624 - 629, 01.01.2026

Belma Gözde Özdemir , Ahmet Bilgi , Cetin Celik , Hilal Arikoglu

https://doi.org/10.18663/tjcl.1838216

Öz

Giriş:BRCA1 mutasyonlu over kanseri, DNA çift sarmal kırıklarının onarımında bozulma ve homolog rekombinasyon yetersizliği ile karakterizedir; bu durum tümör biyolojisini ve terapötik yanıtları belirgin biçimde etkiler. Rekabetçi endojen RNA ağları, kanser progresyonunda önemli düzenleyici mekanizmalar olarak ortaya çıkmıştır. Bu çalışma, BRCA1 mutasyonlu over kanserinde HOTAIR–miR34a–CCND1 ekseninin fonksiyonel ve klinik önemini araştırmayı amaçlamıştır.

Yöntemler:
Yüksek dereceli seröz over kanseri hastalarına ait transkriptomik ve klinik veriler, GDC portalı üzerinden TCGA-OV kohortundan elde edilmiştir. Diferansiyel gen ekspresyon analizi edgeR ile gerçekleştirilmiş; yolak zenginleştirme analizi clusterProfiler ve KEGG kullanılarak yapılmıştır. Sağkalım analizleri Kaplan–Meier eğrileriyle değerlendirilmiştir.

Bulgular:
HOTAIR–miR34a–CCND1 ekseni, BRCA1 mutasyonlu over kanseri dokularında, vahşi tip olgulara kıyasla farklı ekspresyon profilleri göstermiştir. Kaplan–Meier sağkalım analizi, bu genlerin ekspresyon düzeylerine göre genel sağkalımda istatistiksel olarak anlamlı bir fark olmadığını ortaya koymuştur (p > 0.05). Bununla birlikte, KEGG yolak zenginleştirme analizi, bu genlerin kanserle ilişkili mikroRNA yolaklarında yer aldığını göstermiştir; bu durum, doğrudan sağkalım ilişkisinin olmamasına rağmen tümör progresyonunda potansiyel rollerine işaret etmektedir.

Sonuç:
HOTAIR–miR-34a–CCND1 ekseni, BRCA1 mutasyonlu over kanserinde potansiyel bir prognostik biyobelirteç ve terapötik hedef olabilir. Bu da HOTAIR inhibisyonu, miR-34a replasmanı veya PARP ve CDK4/6 inhibitörleriyle kombinasyon gibi yeni tedavi stratejilerinin geliştirilmesini desteklemektedir.

Anahtar Kelimeler

brca1 mutant , over kanseri , hotair , microrna , ccnd1

Etik Beyan

Etik Numarası : 08.10.2025-E.1103897

Destekleyen Kurum

yok

Teşekkür

yok

Functional And Clinical Significance Of The Hotaır–Mir-34a–CCND1 Axis İn Brca1-Mutated Ovarian Cancer

Öz

Objectives:
BRCA1-mutated ovarian cancer is characterized by impaired DNA double-strand break repair and homologous recombination deficiency, leading to distinct tumor biology and therapeutic responses. Competing endogenous RNA networks have emerged as important regulatory mechanisms in cancer progression. This study aimed to investigate the functional and clinical significance of the HOTAIR–miR34a–CCND1 axis in BRCA1-mutated ovarian cancer.
Methods:
Transcriptomic and clinical data of high-grade serous ovarian cancer patients were obtained from the TCGA-OV cohort via the GDC portal. Differential gene expression analysis was performed using edgeR, while pathway enrichment analysis was conducted with clusterProfiler and KEGG. Survival analyses were evaluated using Kaplan–Meier curves.
Results:
The HOTAIR–miR34a–CCND1 axis displayed distinct expression profiles in BRCA1-mutated ovarian cancer tissues compared to wild-type cases. Kaplan–Meier survival analysis revealed no statistically significant differences in overall survival based on the expression levels of these genes (p > 0.05). However, KEGG pathway enrichment analysis demonstrated that these genes are involved in cancer-associated microRNA pathways, suggesting their potential role in tumor progression despite the lack of direct survival association.
Conclusion:
The HOTAIR–miR-34a–CCND1 axis may represent a potential prognostic biomarker and therapeutic target in BRCA1-mutated ovarian cancer, supporting the development of novel strategies such as HOTAIR inhibition, miR-34a replacement, or combination with PARP and CDK4/6 inhibitors.

Anahtar Kelimeler

brca1 mutation , ovarian neoplasms , hotair , micrornas , ccnd1

Etik Beyan

Ethical Number: 08.10.2025-E.1103897

Destekleyen Kurum

none

Teşekkür

none

Kaynakça

• Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin 2023; 73: 17-48.
• Konstantinopoulos PA, Ceccaldi R, Shapiro GI, D'Andrea AD. Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer. Cancer Discov 2015; 5: 1137-54.
• Norquist BM, Harrell MI, Brady MF, Gulsuner S, Dickerson PS, Casadei S et al. Inherited Mutations in Women With Ovarian Carcinoma. JAMA Oncol 2016; 2: 482-90.
• Lord CJ, Ashworth A. PARP inhibitors: Synthetic lethality in the clinic. Science 2017; 355: 1152-8.
• Rinn JL, Chang HY. Genome regulation by long noncoding RNAs. Annu Rev Biochem 2012; 81: 145-66.
• Karreth FA, Pandolfi PP. ceRNA cross-talk in cancer: when cebling rivalries go awry. Cancer Discov 2013; 3: 1113-21.
• Gupta RA, Shah N, Wang KC, Sarma K, Majumdar AS, Maiden ME et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 2010; 464: 1071-6.
• Hermeking H. The miR-34 family in cancer and apoptosis. Cell Death Differ 2010; 17: 193-9.
• Musgrove EA, Caldon CE, Barraclough J, Stone A, Sutherland RL. Cyclin D as a therapeutic target in cancer. Nat Rev Cancer 2011; 11: 558-72.
• Roy R, Chun J, Powell SN. BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer 2011;12: 68-78.
• Asghar U, Witkiewicz AK, Turner NC, Knudsen ES. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov 2015; 14: 130-46.
• Fan L, Lei H, Lin Y, Li S, Zheng J, Lu C et al. Hotair promotes the migration and proliferation in ovarian cancer by miR-222-3p/CDK19 axis. Cell Mol Life Sci 2022; 79: 254.
• Wang W, Zhou Y, Wang J, He J, Xu G, Ma J et al. Targeting Ovarian Cancer Stem Cells by Dual Inhibition of the Long Noncoding RNA HOTAIR and Lysine Methyltransferase EZH2. Mol Cancer Ther 2024; 23: 1666-79.
• Slabáková E, Culig Z, Rem=ík J, SouAek K. Alternative mechanisms of miR-34a regulation in cancer. Cell Death Dis 2017; 8: e3100.
• Nazari M, Babakhanzadeh E, Mollazadeh A, Alikhani-Koupaei J, Ghafouri-Fard S. HOTAIR in cancer: diagnostic, prognostic, and therapeutic perspectives. Cancer Cell Int 2024; 24: 415.